Purpose Modulation of the immune system by the CNS may involve serotonergic regulation via the brain serotonin transporters (SERT). This regulation may be disturbed in patients with CNS disorders including multiple sclerosis (MS). Central serotonergic mechanisms have not been investigated in MS by in vivo imaging. The objective of the study was to assess the availability of SERT in antidepressant-naive patients with MS by means of PET. Methods Included in this study were 23 patients with MS and 22 matched healthy volunteers who were investigated with PET and the SERT-selective marker [ 11 C]DASB, and distribution volume ratios were determined. Clinical assessment of the patients included the expanded disability status scale, the MS fatigue scale Würzburger Erschöpfungsinventar bei MS (WEIMuS) and the Beck Depression Inventory (BDI). The PET data were analysed with both volume-of-interest and voxel-based analyses to determine regional SERT availability. Results Patients had lower SERT availability in the cingulate cortex, the thalamus and the insula, and increased availability in the orbitofrontal cortex. Patients with relapsing/remitting MS tended to have lower SERT in the hippocampus, whereas patients with primary progressive disease showed increased SERT availability in prefrontal regions. There was a positive correlation between SERT availability in the insula and both depression and fatigue scores (r =0.56 vs. BDI, p =0.02; r =0.49 vs. WEIMuS, p =0.05). Conclusion Serotonergic neurotransmission in MS patients is altered in limbic and paralimbic regions as well as in the frontal cortex that this appears to contribute to psychiatric symptoms of MS.
Introduction
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) that is characterized by inflammation, demyelination and axonal injury. Although the aetiology of and susceptibility to MS remain incompletely understood, abundant research indicates a crucial role for immune mechanisms in the pathogenesis of the disease [1] . The brain serotonergic system is involved in modulating the interactions between the nervous and immune systems. For example, in an experimental autoimmune encephalomyelitis (EAE) model, knocking out the serotonin transporters (SERT) has been shown to influence susceptibility to inflammatory infiltrate Florian Then Bergh and Osama Sabri contributed equally to this work. [2] . The SERT inhibitors fluoxetine and sertraline promote remission in acute EAE [3, 4] and have been reported to exert neuroprotective effects in MS. This is supported by clinical data showing reduced frequency of Gd-positive lesions after administration of fluoxetine, which influences antigen presentation by astrocytes and improves neuronal energy homeostasis [5] . Finally, depression and fatigue are frequent in MS and are influenced by serotonergic mechanisms [6, 7] . In a study of the effects of escitalopram on stress-related relapse in women with MS, the risk of relapse related to stressful life events was significantly lower in patients receiving escitalopram than in those continuing their usual treatment [8] , linking depression, the serotonergic system and inflammatory activity of MS in a clinical intervention study. Taken together, these findings suggest a potential role of the central serotonergic system in the autoimmune process and mental manifestations of MS.
So far, in vivo imaging of the brain serotonergic system has not been studied in MS patients. The aim of our study was to investigate SERT availability, as a surrogate for serotonergic activity, using PET and the SERT-selective tracer [ 11 C]DASB in antidepressant-naive patients with MS, and to relate it to the degree of depression and fatigue. We hypothesized that SERT availability (i) is altered in MS patients when compared with healthy controls of similar age and gender, and (ii) is related to depression or fatigue.
Materials and methods

Subjects and clinical evaluation
Included in this study were 21 patients (12 women, 9 men; Table 1 ) with clinically definite MS (according to the criteria of Poser et al. [9] , and the revised criteria of McDonald [10] ), including 15 patients with relapsing/remitting MS (RRMS) and 6 with primary progressive MS (PPMS). Also included were 2 additional patients with a clinically isolated syndrome (CIS; Table 1 ) and imaging criteria indicating dissemination in space (but not in time). The time since resolution of the most recent relapse had to be at least 8 weeks, but was at least 3 months in most patients. Additionally, all patients showed active (Gdenhanced) lesions on MRI performed prior PET imaging. No patient had ever received psychopharmacotherapy or other drugs known to affect brain neurotransmitters. Use of illegal drugs and alcohol abuse were excluded by interview. Severity of disease was assessed using the expanded disability status scale (EDSS) [11] . Fatigue and depression were rated using the MS fatigue scale Würzburger Erschöpfungsinventar bei MS (WEIMuS) [12] and the Beck Depression Inventory (BDI) [13] , respectively (Table 2) . Smoking habits were graded as 0 (nonsmoker) to 3 (heavy smoker; >20 cigarettes per day).
The control subjects included 22 healthy volunteers, selected to match the patients with respect to age and gender (Table 2) . They had no psychiatric or neurologic illness, had no family history of psychiatric disorder and were not taking medication.
The study was approved by the ethics committee of the Medical Faculty of the University of Leipzig (registration number 228-2002) and by the regulatory authorities in Germany (Bundesamt für Strahlenschutz Z-5-22461/2 2004-035, Bundesinstitut für Arzneimittel and Medizinprodukte 61-3900-4022972). The study was performed in accordance with the ICH Guideline for Good Clinical Practice (June 1996 and September 1997) and the declaration of Helsinki. All patients and healthy control subjects gave their written informed consent.
PET imaging
The preparation of [ 11 C]DASB and the scanning procedure were as recently described [14] . Briefly, dynamic PET was performed after intravenous bolus injection of a mean of 425.6 MBq [ 11 C]DASB using an ECAT EXACT HR+ scanner (Siemens, Erlangen, Germany) in two-dimensional acquisition mode in all subjects. The emission scan duration was 90 min acquiring 23 frames. Prior to the emission scan, a 10-min transmission scan (from three 68 Ge sources) was performed for attenuation correction and filtered back-projection with a Hann filter for image reconstruction. After numerical smoothing of reconstructed images (10 mm isotropic Gaussian filter), parametric images of SERT distribution volume ratios (DVR) were generated from the PET data by the multilinear reference tissue model with two parameters (MRTM2) [15] using the cerebellar grey matter as the reference tissue. Regional (volume-of-interest, VOI) analyses of DVRs was performed after coregistration with 3-D MRI data (T1-weighted MPRAGE, obtained on a 1.5-T Magnetom Symphony®; Siemens, Erlangen, Germany) using MultiModality software (HERMES Medical Solutions, Stockholm, Sweden) for realignment and stereotactic normalization (according to the anterior commissure-posterior commissure line) [14] .
Statistical parametric mapping (SPM2; Wellcome Department of Cognitive Neurology, UK) was used to compare PET datasets from MS patients (sub)group(s) with those from the 22 healthy controls. For this purpose, mean images (70-90 min after injection) were spatially normalized onto the SPM2 integrated PET template and smoothed with 12 mm full-width at half-maximum on a Gaussian filter. Thresholds were set at p <0.005, uncorrected, with a minimum of 30 voxels.
SERT genotyping
SERT genotype variation functionally related to states potentially affecting phenotype was assessed. Therefore, DNA was isolated from 2 mL peripheral blood, and polymerase chain reaction and visualizations of both the SERT length polymorphism in the promoter region (SERT-LPR) and the variable tandem repeat polymorphism in intron 2 (STin2-VNTR) were performed as recently described [14] .
Statistical analysis
Statistical analyses were performed with PASW 18 for Windows (IBM SPSS; Somers, NY) and R version 2.14.0 [16] . For the VOI analyses, repeated measures analysis of variance (ANOVA) was used to evaluate differences in the means between the study groups for given regions of the brain, where the within-subject effects compared left and right hemispheres. For anatomical structures that are centrally located, a 'simple' ANOVA was performed (i.e. a t test). Pearson correlations were determined to reveal associations between DVRs and clinical variables in MS patients. An alpha adjustment with respect to multiple testing was not performed due to the primarily exploratory character of the study. Statistical significance was set at p <0.05.
Results
The SPM analysis performed for the entire group revealed that MS patients had lower activity than controls in many subcortical and some cortical areas, as indicated in Fig. 1a . When analysing clinically defined subgroups, MS patients with either RRMS or PPMS showed reduced activity in the cingulate cortex. However, differential patterns were also apparent, as shown in Fig. 1b , c.
Both RRMS and PPMS patients had lower activity in areas close to the midline, more pronounced in PPMS patients. In contrast, only the PPMS patients showed markedly increased activity in the frontal and especially the orbitofrontal cortex. Direct comparison of these groups confirmed that the decrease in subcortical areas, the hippocampus and the midbrain were more pronounced in PPMS patients, and that higher SERT availability in the frontal areas characterized PPMS patients RRMS Relapsing/remitting MS, PPMS primary progressive MS, CIS clinically isolated syndrome, SERT-LPR polymorphism in the promoter region of the serotonin-transporter coding gene in SLC6A4, STin2-VNTR variable number of tandem repeats in the second intron of SLC6A4 not only versus healthy controls but even compared to other MS patients (Fig. 1d) . Using a different approach to assess regional differences and interhemispheric asymmetries, VOI analysis of SERT availability showed that the DVR of the hippocampus in MS patients did not differ significantly between left and right (p =0.3) whereas the values on the left in the healthy controls were much higher than on the right (p =0.001). As a result (see also Fig. 2) , there was a significant interaction term for left/right and group (p =0.007). In the thalamus and hypothalamus, the MS group had significantly reduced values (p =0.01 and p =0.02, respectively) with very small difference between left and right (p =0.05) for the thalamus. Also, insular DVR showed significant differences between MS patients and healthy controls (p =0.03) with higher values on the right (p =0.0006). In the other brain regions analysed, no significant group effects were present and the p values ranged from 0.2 to 0.6.
When analysing SERT availability in relation to clinical variables, DVR in the insular region was positively correlated with the degree of depression (BDI; r =0.53, p =0.01) and fatigue (WEIMuS; r =0.43, p =0.04) when including all MS patients (Fig. 3) . Excluding one outlier each, the correlations for the insular DVR was no longer significant (BDI, p =0.3; WEIMuS, p =0.2). EDSS was not significantly correlated with DVR in any brain region, nor was BDI or WEIMuS for other brain regions.
Discussion
In the present study, the first to directly investigate SERT availability in MS in vivo, patients with MS had abnormally low SERT availability in cortical and subcortical brain areas.
These abnormalities involved limbic and paralimbic regions such as the cingulate cortex, and were seen across MS subtypes. Lower hippocampal/parahippocampal SERT availability was found in patients with RRMS, while higher SERT availability in the orbitofrontal cortex was found particularly in patients with PPMS. Insular SERT availability was related to depression and fatigue.
These findings corroborate recent PET findings of diminished SERT availability in the anterior cingulate cortex and decreased 5-HT 1A receptor binding in patients with chronic fatigue syndrome [17, 18] indicating that 5-HT neurotransmission plays a role in the pathophysiology of fatigue, either as a primary feature of fatigue or a finding secondary to other processes such as depression or neurodegeneration. Hence, these changes may occur because (i) synaptic serotonin is maintained by SERT or (ii) the central serotonin system exerts a homeostatic function. Such regionally distinct differences in SERT availability then reflect a network pattern necessary to modulate behaviour, acting on disturbed brain homeostasis, thus determining the phenotype. A change in such a network might represent the neural substrate for altered emotion processing and an impaired affective state [19] . Functional adaptation can be assumed for the hippocampus-cingulate system, which is crucial for memory processing and sensitive to cognitive intervention, and also in patients with MS [20, 21] . According to our data, alterations in serotonergic tone might underlie these changes and are in line with other findings that have demonstrated the effects of fluoxetine on neuroplasticity [5] and limbic abnormalities using magnetization transfer ratio imaging [22] . Furthermore, a quantitative neuroimaging study using 3-T MRI including diffusion tensor imaging and 3-D T1-weighted volume acquisition has shown structural and ultrastructural alterations in subcortical limbic components even beyond the hippocampus, related to the performance of episodic recall in MS patients with mild memory dysfunction [23] . Such cognitive tests were not performed in our study. We did not find a correlation between SERT availability and EDSS, and this raises the question as to whether SERT changes reflect stage-dependent functional alterations as dying-back effects in either white or grey matter pathology. Hence, one might speculate that changes at the neurotransmitter level (together with inflammatory forms [24] ) reflect a secondary reaction to noninflammatory progressive MS; if this were true, patients with CIS or even presymptomatic MS would not show the same effects, since in patients with early MS, brain plasticity can be preserved despite a high burden of cerebral pathology [25] . Recovery-oriented treatment strategies should therefore be started at an early disease stage, given that the described network alterations have already been found in patients with CIS at presentation [26, 27] . Similarly, a recent study of functional connectivity patterns has indicated such a type of brain reserve (within the default mode network) in patients with early MS showing strong and diffuse reductions in white matter integrity [28] . Differential changes in RRMS and PPMS may alternatively indicate that separate networks, both employing serotonergic transmission, are dysregulated and may serve different purposes in MS or, more generally, CNS disorders.
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Our findings also suggest that the levels of depressive symptoms or fatigue, which were both present in our MS patients, are related to SERT binding in the insular cortex: patients with more severe depression or fatigue had higher SERT availability due to relatively reduced serotonergic neurotransmission, probably as a result of insufficient compensation of the adaptive system. The nonrobust nature of these findings implies that further research should be performed to test this hypothesis, especially since other authors have reported lower SERT availability (in the basal ganglia and limbic circuits) related to fatigue and to a disrupted integrity or damage to serotonergic fibres in Parkinson's disease [29] . The interpretation of the results of our pilot study is hampered by the size and heterogeneity of the sample despite the fact that we found SERT changes across the subtypes of MS investigated in this study. For example, when testing the data from the few patients with glatimer acetate in relation to the date from the RRMS patients who did not receive this immune-modulatory treatment, the regions of altered SERT availability were the same, but the degree of reduction differed with less involvement in the patients treated with glatimer acetate. This preliminary finding suggests an influence of immune-modulatory treatment on SERT availability as a homeostatic marker at the interface between adaptive brain and the immune system, probably in terms of a rebalance or reconstitution of the altered anterior limbic network. This is in line with a compensatory mechanism as mentioned above, and needs further prospective comparative investigations in order to disentangle the causal association between immune pathogenesis and the brain serotonin system. Furthermore, we did not account for the volume and distribution of demyelinating lesions, or correct for disease duration. When stratified for lesion load, asymmetries of SERT availability, which have been found in other samples of healthy patients [30] and patients with temporal lobe epilepsy [31] , might be explained, but not the involvement of the demonstrated network. For the assessment of susceptibility it is also of interest as to whether there is an effect of the less functional active genotypes (e.g. homozygote carriers of SS and 296/STin2.12) on SERT availability in disease versus healthy controls.
Conclusion
In summary, serotonergic neurotransmission is altered in MS and appears to contribute to the pathophysiology of depression and fatigue. There may be further effects on adaptive coping or resistance mechanisms.
